{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:18Z","timestamp":1772166318536,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The familial chylomicronemia syndrome (FCS) is an ultra rare disease caused by lipoprotein lipase (LPL) deficiency associated with potentially lethal acute pancreatitis risk. Thrombocytopenia (platelet count\u2009&lt;\u2009150,000\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L) has been reported in patients with FCS, treated or not with volanesorsen, a second generation APOC3 anti-sense oligonucleotide. Chylomicrons are the lipoproteins delivering fat after a meal and FCS thus has a post-prandial origin. Platelet count and function have not been studied post-prandially in FCS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate post-prandial fluctuations in the platelet count (PLC) and functional defects of hemostasis in FCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PLC, functional defects in hemostasis and hematologic variables were measured up-to 5\u00a0h after a meal in 6 homozygotes for FCS causing gene variants (HoLPL), 6 heterozygotes for LPL loss-of-function variants (HeLPL) and 7 normolipidemic controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hourly post-prandial PLC was significantly lower in HoLPL than in controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.009). Compared to the other groups, the PLC tended to decrease rapidly (in the first hour) post-meal in HoLPL (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03) and remained lower than baseline 5-h post-meal (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02) whereas it tended to slightly increase in normolipidemic controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). Platelet function was not affected by the prandial status. In HoLPL, post-prandial fluctuations in the PLC positively correlated with the lymphocyte count (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005) and negatively with neutrophil\/lymphocyte ratio (NLR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PLC decreases post-prandially in FCS (HoLPL), is not associated with changes in functional defects of hemostasis and correlates with the NLR, a marker of acute pancreatitis severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02743-0","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T03:01:58Z","timestamp":1687834918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome"],"prefix":"10.1186","volume":"18","author":[{"given":"Miriam","family":"Larouche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"5","key":"2743_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","volume":"12","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, O\u2019Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol. 2018;12(5):1234-43 e5.","journal-title":"J Clin Lipidol"},{"key":"2743_CR2","unstructured":"Brunzell JD, Deeb SS. Familial Lipoprotein Lipase Deficiency, Apo C-II Deficiency, and Hepatic Lipase Deficiency. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill Education; 2019."},{"issue":"11","key":"2743_CR3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1161\/01.ATV.12.11.1336","volume":"12","author":"JR Patsch","year":"1992","unstructured":"Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12(11):1336\u201345.","journal-title":"Arterioscler Thromb."},{"issue":"1","key":"2743_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0021-9150(94)90085-X","volume":"106","author":"F Karpe","year":"1994","unstructured":"Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106(1):83\u201397.","journal-title":"Atherosclerosis"},{"issue":"2","key":"2743_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5551\/jat.RV16003","volume":"24","author":"D Masuda","year":"2017","unstructured":"Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24(2):95\u2013109.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"2743_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"2743_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347.","journal-title":"N Engl J Med"},{"issue":"23","key":"2743_CR8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"2743_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jacl.2017.04.043","volume":"11","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Baass A, Tremblay K, Brisson D, Laflamme N, Paquette M, et al. Natural history (up to 15 years) of platelet count in 84 patients with familial hyperchylomicronemia due to lipoprotein lipase deficiency. J Clin Lipidol. 2017;11(3):797\u20138.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2743_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/09537100600930946","volume":"18","author":"L Wiens","year":"2007","unstructured":"Wiens L, Lutze G, Luley C, Westphal S. Platelet count and platelet activation: impact of a fat meal and day time. Platelets. 2007;18(2):171\u20133.","journal-title":"Platelets"},{"issue":"4","key":"2743_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2013.08.003","volume":"25","author":"EM Greenberg","year":"2013","unstructured":"Greenberg EM, Kaled ES. Thrombocytopenia. Crit Care Nurs Clin North Am. 2013;25(4):427\u201334.","journal-title":"Crit Care Nurs Clin North Am."},{"issue":"2","key":"2743_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00231536","volume":"113","author":"MR Hayden","year":"1992","unstructured":"Hayden MR, Ma Y. Molecular genetics of human lipoprotein lipase deficiency. Mol Cell Biochem. 1992;113(2):171\u20136.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2743_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000331494","volume":"11","author":"B Azab","year":"2011","unstructured":"Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology. 2011;11(4):445\u201352.","journal-title":"Pancreatology"},{"issue":"21","key":"2743_CR14","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.3748\/wjg.v23.i21.3883","volume":"23","author":"TJ Jeon","year":"2017","unstructured":"Jeon TJ, Park JY. Clinical significance of the neutrophil-lymphocyte ratio as an early predictive marker for adverse outcomes in patients with acute pancreatitis. World J Gastroenterol. 2017;23(21):3883\u20139.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2743_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2743_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","volume":"31","author":"LF Reeskamp","year":"2020","unstructured":"Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31(3):140\u20136.","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"2743_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.20140391","volume":"212","author":"U Flierl","year":"2015","unstructured":"Flierl U, Nero TL, Lim B, Arthur JF, Yao Y, Jung SM, et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med. 2015;212(2):129\u201337.","journal-title":"J Exp Med"},{"issue":"3","key":"2743_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/nat.2016.0650","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, et al. The effects of 2\u2019-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 2017;27(3):121\u20139.","journal-title":"Nucleic Acid Ther"},{"key":"2743_CR19","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense technology: a review. J Biol Chem. 2021;296:100416.","journal-title":"J Biol Chem"},{"issue":"2","key":"2743_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.2020.260059","volume":"107","author":"MHL Slingsby","year":"2022","unstructured":"Slingsby MHL, Vijey P, Tsai IT, Roweth H, Couldwell G, Wilkie AR, et al. Sequence-specific 2\u2019-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates. Haematologica. 2022;107(2):519\u201331.","journal-title":"Haematologica"},{"issue":"3","key":"2743_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacl.2017.04.039","volume":"11","author":"K Tremblay","year":"2017","unstructured":"Tremblay K, Brisson D, Gaudet D. Gene expression signature of platelet count in lipoprotein lipase deficiency. J Clin Lipidol. 2017;11(3):795.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2743_CR22","first-page":"449","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449\u201358.","journal-title":"Thromb Haemost"},{"issue":"7","key":"2743_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3109\/09537104.2014.979340","volume":"26","author":"S Balta","year":"2015","unstructured":"Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680\u20131.","journal-title":"Platelets"},{"key":"2743_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2018.01.015","volume":"479","author":"I Ramasamy","year":"2018","unstructured":"Ramasamy I. Update on the laboratory investigation of dyslipidemias. Clin Chim Acta. 2018;479:103\u201325.","journal-title":"Clin Chim Acta"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02743-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T03:08:06Z","timestamp":1687835286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02743-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2743"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02743-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2443467\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave their informed consent to participate in this study. This project was conducted as part of the SMASH research program (SMASH: Systems and Molecular Approaches of Severe Hyperlipidemias) and was approved by an authorized ethics review board, namely IRB services (Advarra).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors agree to publish the presented results. Publishing the results of clinical projects\/trials is part of the consent provided by all participants in the SMASH program.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}